Pharma Vietnam: Vinphaco at Vietnam’s National Pharmacovigilance Conference 2026

On 3 October 2026, Vietnam’s National Pharmacovigilance Conference brought together healthcare professionals and specialists to discuss the development of pharmacovigilance practice, with a focus on digital transformation, integration and development. Organised by the National Drug Information and Adverse Drug Reaction (DI&ADR) Centre at Hanoi University of Pharmacy in collaboration with the Regional DI&ADR Centre in Ho Chi Minh City at Cho Ray Hospital, the conference was delivered online via Zoom Webinar.

For the pharma Vietnam sector, pharmacovigilance is an important part of the broader pharmaceutical quality landscape. Alongside manufacturing controls and quality management, post-marketing safety monitoring helps stakeholders evaluate medicine safety throughout the product lifecycle

For pharmaceutical manufacturers and international supply partners, pharmacovigilance is relevant to the broader lifecycle of a medicine. It connects information from healthcare practice with the ongoing assessment of a product’s safety profile and the management of potential risks after marketing.

Vietnam’s National Pharmacovigilance Conference: Key Priorities

The 2026 conference was held under the theme “Pharmacovigilance Practice in Vietnam: Digital Transformation, Integration and Development.” Its programme addressed developments in pharmacovigilance practice, digital transformation in line with international standards, risk identification, patient-specific considerations and the safe use of high-risk medicines.

The conference was organised through collaboration between the National DI&ADR Centre and the regional centre based at Cho Ray Hospital. Its online format enabled healthcare professionals interested in clinical pharmacy and pharmacovigilance to participate.

These discussions reflect the importance of strengthening the way medicine safety information is collected, assessed, communicated and used in healthcare practice

.

Why digital transformation matters in pharmacovigilance

Digital transformation can support the management and analysis of medicine safety information. Better structured data and more effective information exchange may help relevant professionals identify patterns and assess potential safety signals.

However, digital tools do not replace clinical assessment, scientific judgement or appropriate follow-up. The value of pharmacovigilance depends on the quality of the information collected, the methods used to evaluate it and the actions taken when a potential risk is identified.

The conference’s focus on digital transformation therefore provides a useful perspective on the continuing development of Vietnam’s medicine safety infrastructure.

Pharmacovigilance and Pharmaceutical Manufacturing Quality

For international pharmaceutical buyers, evaluating a manufacturer involves more than reviewing its manufacturing facilities and quality certifications. Understanding how product safety is considered throughout the medicine lifecycle is also relevant.

Pharmacovigilance supports the monitoring of suspected adverse drug reactions and the evaluation of potential risks associated with medicines in clinical use. When relevant safety information becomes available, appropriate assessment and follow-up help inform decisions about the product’s benefit–risk profile.

Several aspects are important to this process:

• Post-marketing safety monitoring: Medicine safety information may continue to emerge after a product enters routine clinical use.
• Reporting and assessment: Suspected adverse drug reactions need to be documented and evaluated through the applicable pharmacovigilance processes.
• Risk management: Relevant findings may require further assessment and appropriate action under applicable regulatory requirements.
• Communication: Timely exchange of safety information among relevant stakeholders supports informed decision-making.

Pharmacovigilance is therefore an important part of pharmaceutical quality accountability. It complements, rather than replaces, good manufacturing practices, quality control and other applicable quality-system requirements.

For international partners, these functions should be evaluated through appropriate documentation, regulatory evidence and discussions with the manufacturer. Attendance at an industry conference alone does not establish the maturity or effectiveness of a company’s pharmacovigilance system.

Digital Transformation and Its Relevance to International Supply Partners

International pharmaceutical partnerships operate across different regulatory environments, healthcare systems and reporting practices. The management of medicine safety information is consequently relevant to both manufacturers and their partners.

Digital tools may help improve data handling and information exchange, while consistent reporting and appropriate assessment remain essential to the interpretation of safety information.

For importers and distributors, practical questions include how suspected adverse drug reactions should be communicated, which parties are responsible for reporting, how safety information is escalated and what local regulatory requirements apply.

These responsibilities should be clearly defined for each market and product. Regulatory obligations are not identical across all countries, and partners should confirm the applicable requirements with the relevant authorities and qualified regulatory professionals.

For manufacturers in Vietnam serving international markets, engagement with developments in the national pharmacovigilance environment can provide useful industry context. It does not, by itself, demonstrate compliance with every importing country’s requirements.

VINPHACO and the Broader Pharmaceutical Quality Perspective

VINPHACO’s pharmaceutical manufacturing activities form part of a broader quality framework that includes manufacturing operations, quality management and the supply of medicines to healthcare markets.

The company’s current profile describes a manufacturing system that includes sterile production, lyophilized injectables, BFS technology and non-sterile dosage forms. It also identifies quality systems and standards including GMP-WHO, GLP, GSP, GDP and ISO 9001:2015. The precise scope and current status of any certification should be confirmed for the relevant facility and market.

Participation in professional discussions about pharmacovigilance can be considered alongside other forms of engagement with the pharmaceutical and healthcare sectors. Such engagement helps place manufacturing within the wider context of medicine quality and patient safety.

For international buyers exploring pharma Vietnam manufacturers, understanding the distinction between manufacturing quality systems and pharmacovigilance responsibilities is essential. These areas are related, but they require separate evidence and assessment.

A Lifecycle Perspective on Medicine Quality

The National Pharmacovigilance Conference 2026 brought attention to the continuing development of medicine safety practices in Vietnam, particularly the role of digital transformation and integration.

For the pharma Vietnam industry, this is a reminder that pharmaceutical quality is not limited to the manufacturing stage. Manufacturing controls and quality systems remain fundamental, while post-marketing safety monitoring contributes to the ongoing assessment of medicines in clinical use.

For international supply partners, a comprehensive assessment should consider both documented manufacturing capability and the applicable arrangements for post-marketing safety responsibilities.

At VINPHACO, pharmaceutical manufacturing capabilities and quality systems provide the context for these wider industry discussions. As international partnerships develop, clear communication, appropriate documentation and an understanding of market-specific regulatory requirements remain important to responsible pharmaceutical supply.

To learn more about VINPHACO’s manufacturing capabilities and international business activities, visit the company’s official website or contact its international business team through the appropriate company contact channel.